Addition Therapeutics

SOUTH SAN FRANCISCO, CA · Founded 2021 · CIK 0002102340 · Biotech · Private

Small molecule therapeutics targeting severe genetic and rare diseases

additiontx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$28M
1 Form D · Dec 2025
9 months since last filing
Contracts
—
No federal contracts on record
Patents
11
0 granted · 11 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$28,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2537BIOIO, LLC——
2538EIKONIZO THERAPEUTICS, INC.—$2.4M
2539Topos Bio, Inc.—$9.0M
2540Addition Therapeutics—$28M
2541NBO Pharma Inc.—$7.6M
2542Apriori Bio——
2543Trekka Therapeutics, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Peter BisgaardDirector
  • Kathleen CollinsDirector
  • Lawrence KongExecutive Officer
  • Jennifer LeeDirector
  • Ronald ParkDirector · Executive Officer
  • Matthew PattersonDirector
  • Jayson PunwaniDirector
  • Laetitia SchwabDirector

Patents

USPTO · 0 granted of 11
  • Genome Insertions In Cellsapplication
  • Rna Tails For Target Primed Reverse Transcriptionapplication
  • Nucleic Acid Insertion In Young Mammalsapplication
  • Multicomponent Systems For Site-specific Genome Modificationsapplication
  • Compositions For Target Primed Reverse Transcriptionapplication
  • Rna Tails For Target Primed Reverse Transcriptionapplication
  • Nucleic Acid Insertion In Young Mammalsapplication
  • Multicomponent Systems For Site-specific Genome Modificationsapplication
  • Genome Insertions In Cellsapplication
  • Compositions For Target Primed Reverse Transcriptionapplication
  • Genome Insertions In Cellsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.